Oral Administration of β-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial

2017 ◽  
Vol 20 (5) ◽  
pp. 458-464 ◽  
Author(s):  
Gadi Lalazar ◽  
Ehud Zigmond ◽  
Sarah Weksler-Zangen ◽  
Ami Ben Ya'acov ◽  
Miriam Sklair Levy ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Oral Administration ◽  
Nonalcoholic Steatohepatitis ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Metformin for Prevention of Weight Gain and Insulin Resistance with Olanzapine: A Double-Blind Placebo-Controlled Trial

2006 ◽  
Vol 51 (3) ◽  
pp. 192-196 ◽  
Author(s):  
Trino Baptista ◽  
Jessan Martínez ◽  
Anny Lacruz ◽  
Nairy Rangel ◽  
Serge Beaulieu ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Weight Gain ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

Creatine supplementation does not promote additional effects on inflammation and insulin resistance in older adults: A pilot randomized, double-blind, placebo-controlled trial

2020 ◽  
Vol 38 ◽  
pp. 94-98
Author(s):  
Camila L.P. Oliveira ◽  
Barbara de Moura Mello Antunes ◽  
Aline Corado Gomes ◽  
Fábio Santos Lira ◽  
Gustavo Duarte Pimentel ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Older Adults ◽  
Controlled Trial ◽  
Creatine Supplementation ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effects of synbiotic supplementation on metabolic parameters and apelin in women with polycystic ovary syndrome: a randomised double-blind placebo-controlled trial

2018 ◽  
Vol 119 (4) ◽  
pp. 398-406 ◽  
Author(s):  
Elham Karimi ◽  
Ashraf Moini ◽  
Mehdi Yaseri ◽  
Nooshin Shirzad ◽  
Mahdi Sepidarkish ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Mean Difference ◽  
Metabolic Parameters ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Synbiotic Supplementation

AbstractPolycystic ovary syndrome (PCOS) is one of the most common causes of infertility in women of reproductive age. Insulin resistance is a main pathophysiologic feature in these patients. According to some studies, the intake of probiotic bacteria may improve glucose homoeostasis. The aim of this study was to investigate the effect of synbiotics on metabolic parameters and apelin in PCOS patients. This randomised double-blind placebo-controlled trial was conducted on eighty-eight PCOS women aged 19–37 years old. The participants were randomly assigned to two groups receiving (1) synbiotic supplement (n44), and (2) placebo (n44) for 12 weeks. Fasting blood samples were taken at baseline and after 12 weeks. The two groups showed no difference in fasting blood sugar (adjusted mean difference: 0·60; 95 % CI −3·80, 5·00,P=0·727), plasma glucose fasting 2-h (adjusted mean difference 2·09; 95 % CI −9·96, 14·15,P=0·134), HbA1c (adjusted mean difference 0·06; 95 % CI −0·09, 0·22,P=0·959), homoeostatic model assessment-insulin resistance (HOMA-IR) (adjusted mean difference: 0·02; 95 % CI −0·99, 1·03,P=0·837), quantitative insulin sensitivity check index (QUICKI) (adjusted mean difference: −0·02; 95 % CI −0·33, 0·29,P=0·940) and C-reactive protein (CRP) (adjusted mean difference: 0·24; 95 % CI −1·61, 2·08,P=0·141) by the end of the intervention. A significant difference was observed in the mean apelin 36 before and after the intervention between synbiotic and placebo groups (adjusted mean difference: −4·05; 95 % CI −7·15, −0·96,P=0·004). A 12-week synbiotic supplementation has no significant beneficial effects on HOMA-IR and CRP in PCOS patients, whereas the level of apelin 36 significantly decreased.

scholarly journals Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 9 ◽  
Author(s):  
Ke Chen ◽  
Changqi Liu ◽  
Hua Li ◽  
Yuehua Lei ◽  
Chenggui Zeng ◽  
...  
Keyword(s):  
Oral Administration ◽  
Controlled Trial ◽  
Bifidobacterium Longum ◽  
Intervention Group ◽  
Infantile Colic ◽  
Double Blind ◽  
Pediococcus Pentosaceus ◽  
Double Blind Placebo ◽  
Colony Forming Units

Background: Colic is a common condition in infants <4 months of age. Attempts to treat infantile colic with probiotics have shown variable efficacy and overall low evidence of success. In this work, we tested the hypothesis that oral administration of Bifidobacterium longum CECT7894 (KABP042) and Pediococcus pentosaceus CECT8330 (KABP041) mix (1 × 109 colony forming units) would improve the symptoms of infantile colic.Methods: A total of 112 exclusively breastfed or mixed fed infants aged <2 months and meeting the ROME IV criteria for infantile colic were recruited. The infants were randomized in a double-blind, placebo-controlled trial to receive orally administered probiotics (intervention group, IG, n = 48) or placebo (placebo group, PG, n = 42) daily for 21 days.Results: Infants in the IG had significantly shorter crying time (p < 0.001) on day 7 [IG vs. PG, median (25−75th percentile): 38 (3.5–40.5) vs. 62 (40–108) min/day], day 14 [IG vs. PG: 20 (0–40) vs. 50 (30–75) min/day], and day 21 [IG vs. PG: 14 (0–33) vs. 40 (28–62) min/day]. Higher responder ratio and fewer crying/fussing episodes on days 7, 14, and 21 and better stool consistency on day 21 were observed in the IG (p < 0.01) as compared to the PG. Conversely, no significant effects on stool frequency or quality of life were observed.Conclusions: In summary, daily oral administration of B. longum CECT7894 (KABP042) and P. pentosaceus CECT8330 (KABP041) was an effective treatment for shortening crying time due to infantile colic and for improving fecal consistency. This trial was registered retrospectively in December 2019 with a trial number of ISRCTN92431452.

Sign in / Sign up

Export Citation Format

Share Document